Department of Orthopaedics, School of Medicine, Southern Medical University Guangzhou, Jinling Hospital, 305 East Zhongshan Road, Nanjing 210002, Jiangsu Province, China.
J Orthop Res. 2010 Dec;28(12):1621-5. doi: 10.1002/jor.21178.
Reversion-inducing cysteine-rich protein with Kazal motifs (RECK), a novel membrane-anchored matrix metalloproteinase inhibitor, have been shown to be associated with prognosis and suppress tumor progression through angiogenesis inhibition in many cancers. In this study, the expression of RECK in osteosarcoma was examined, and its clinical significance was firstly evaluated. RECK expression was immunohistochemically examined in osteosarcoma from 49 patients. By summing intensity and proportion scores, these patients were categorized as weak and strong. RECK expression in the primary tumor was strong in 27 patients (55.1%) and was weak in the rest of the patients. The 5-year survival rate of patients with RECK-strong tumor (81.5%) was significantly higher than that of patients with RECK-weak tumor (36.4%; p = 0.003). Reduced RECK expression significantly correlated with metastasis (p = 0.010) and recurrence (p = 0.004). A multivariate analysis confirmed that reduced RECK expression was an independent and significant factor to predict a poor prognosis (p = 0.017). RECK status is a useful prognostic factor in osteosarcoma, and an independent prognostic factor contributing to the determination of more adequate therapy strategies for each patient.
富含半胱氨酸的天冬氨酸蛋白水解酶抑制因子（RECK），一种新型的膜锚定基质金属蛋白酶抑制剂，在许多癌症中通过抑制血管生成与预后和抑制肿瘤进展有关。本研究检测了骨肉瘤中 RECK 的表达情况，并首次评估了其临床意义。采用免疫组织化学方法检测 49 例骨肉瘤患者中 RECK 的表达。通过对强度和比例评分进行求和，将这些患者分为弱表达和强表达。27 例患者（55.1%）原发肿瘤中 RECK 表达较强，其余患者表达较弱。RECK 强表达肿瘤患者的 5 年生存率（81.5%）明显高于 RECK 弱表达肿瘤患者（36.4%；p = 0.003）。RECK 表达降低与转移（p = 0.010）和复发（p = 0.004）显著相关。多因素分析证实，RECK 表达降低是预测不良预后的独立和显著因素（p = 0.017）。RECK 状态是骨肉瘤的一个有用的预后因素，是决定每个患者更适当治疗策略的独立预后因素。
